P

Paratek Pharmaceuticals Inc
F:N4CN

Watchlist Manager
Paratek Pharmaceuticals Inc
F:N4CN
Watchlist
Price: 2.024 EUR Market Closed
Market Cap: €115.9m

Net Margin

-41.7%
Current
Declining
by 0.4%
vs 3-y average of -41.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-41.7%
=
Net Income
$-62.7m
/
Revenue
$177m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-41.7%
=
Net Income
€-62.7m
/
Revenue
$177m

Peer Comparison

Country Company Market Cap Net
Margin
US
Paratek Pharmaceuticals Inc
F:N4CN
115.9m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
975.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
549.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.3B EUR
Loading...

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 15 072 companies
20th percentile
-41.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Paratek Pharmaceuticals Inc
Glance View

Market Cap
115.9m EUR
Industry
Pharmaceuticals

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

N4CN Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-41.7%
=
Net Income
$-62.7m
/
Revenue
$177m
What is Paratek Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Paratek Pharmaceuticals Inc is -41.7%, which is below its 3-year median of -41.3%.

How has Net Margin changed over time?

Over the last 3 years, Paratek Pharmaceuticals Inc’s Net Margin has increased from -412.3% to -41.7%. During this period, it reached a low of -412.3% on Jun 30, 2020 and a high of -38.7% on Jun 30, 2023.

Back to Top